Oncology Research

TruSight Oncology 500 offers wide variety of benefits in analyzing multiple tumor variant types in 523 genes in a single assay. It is a next-generation sequencing (NGS) assay that enables comprehensive genomic profiling of tumor samples. The assay is highly effective in identifying all types of relevant DNA and RNA variants in different types of solid tumors including lung, melanoma, ovarian, breast, gastric, bladder, sarcoma etc.

Also, the assay is highly accurate in measuring immuno-oncology biomarkers such as microsatellite instability (MSI) and tumor mutational burden (TMB).

Our TST170 Panel is also validated on ctDNA. It also provides an indepth view into cancer genetics, effective in assessing fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications.

Discover Your Application

Solutions for cells, blood, tissues, FFPE with varying quality and quantity inputs

TruSight Oncology 500

  • Single comprehensive NGS assay to target 523 key immuno-oncology biomarkers for assessment of all DNA and RNA variant types, plus MSI and TMB
  • Compatible with ctDNA, DNA and RNA inputs

TruSight Tumor 170
(TST 170)

  • Single NGS assay that covers 170 genes associated with common solid tumors
  • Assess fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications
  • Highly sensitive assay enables variant detection as low as 5% mutant allele frequency using as little as 40 ng DNA and RNA input

Service Highlights

  • End-to-end solution for comprehensive genomic grofiling of tumor samples
  • Expertise in processing a variety of Sample Types - FFPE/tissue (DNA & RNA), Plasma (ctDNA)
  • Streamlined validated workflow with quick turnaround times for TST170/TSO500 assay
  • Powerful bioinformatics pipelines for additional insights (drug-gene interactions, identification of actionable mutations, comprehensive reports)

BioFX Transcriptome Analysis

  • Streamlined pipeline for fast & scalable analysis
  • Customized reporting
  • Interactive reports
  • Publication-ready figures
  • Improve data interpretation with support from MedGenome's team of experts


Explore Analysis Reports

BioFX’s transcriptome analysis platform was built using state-of-the-art analysis tools for gene expression, differential expression, pathway enrichment, splicing and fusion analysis and more.

Detailed data quality,
alignment and coverage stats

Oncoplot showing the somatic
mutations in the top 20 most
frequently mutated genes.

Summary statistics of mutations
by sample.

Drug gene interaction plot shows potential known/reported drug-gene interactions or Druggable categories for the 20 most frequently mutated genes.

Lollipop plots showing
variants for genes


Ordering and Data Delivery

MedGenome’s customer portal allows for easy sample submission and sample tracking during lab processing. Data QC, raw data and interactive analysis reports are delivered securely through customer portal.

White Papers and Technical Resources

MedGenome Inc. Services with Illumina’s TruSight Oncology 500 (TSO 500)

Illumina’s TSO 500 is a comprehensive assay that enables comprehensive genomic profiling of tumor samples. It is a single workflow identifying DNA and RNA variants from the same sample. It can detect InDels, SNVs, CNV, fusions and splice variants. It also measures biomarkers like Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) using limited sample input. MedGenome uses propriety analysis pipeline along with Illumina’s Basespace platform to analyze data providing high sensitivity and specificity to provide a comprehensive cancer genomic profile.

2023 © MedGenome • All Rights Reserved
Request a Quote